Cullinan's Zipalertinib Plus Chemotherapy Extends PFS By 6 Months In EGFR Ex20+ Lung Cancer

India, Sept. 13 -- Cullinan Therapeutics, Inc (CGEM), Taiho Oncology and Taiho Pharmaceutical reported additional results from the Phase 3 REZILIENT3 trial of Zipalertinib plus platinum-based chemotherapy in first-line treatment of patients with advanced EGFR exon 20 insertion-mutated non-small cell lung cancer (NSCLC).

The combination extended median progression-free survival (PFS) by 6 months compared with chemotherapy alone.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer; with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations found in up to 4% of cases globally. These mutations are associated with limited treatment options and poorer outcomes compared with more common EGFR mutation...